chevron_leftBack
As of 13 June 2026, Phathom Pharmaceuticals, Inc. has a market cap of $935.69M USD, ranking #11082 globally and #2206 in the United States.
It ranks #1000 in the Healthcare sector, and #374 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$935.69MUSD
Enterprise Value
$1.36BUSD
Revenue (TTM)
$175.11MUSD
EBITDA (TTM)
-$159.35MUSD
Net Income (TTM)
-$221.25MUSD
EBITDA Margin
-91%
Profit Margin
-126%
PS Ratio
5.1
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Steven Basta
open_in_new
Employees
371
Founded
2018
IPO
25 Oct 2019
Website
phathompharma.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 4% | 0.4% | 11% | -15% | -13% | 184% |
News
Loading...
PHAT Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
PHAT
Phathom Pharmaceuticals Inc Ordinary shares
ISIN: US71722W1071
Shares Out.:
Shares Outstanding:
79.756M1
Shares Float:
56.879M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
11.78 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
81K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
58K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
38K%
|
97.4
|
|
NYSE: MRK
|
$274.03B
29K%
|
15.1
|
|
NYSE: PFE
|
$149.38B
16K%
|
19.5
|
|
NYSE: BMY
|
$117.58B
12K%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$321.52B
34K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
31K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
29K%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.82B
19K%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.1B
12K%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.46B
11K%
80.96B GBP
|
14.6
|
chevron_leftBack